Not checked for notices yet.
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Bijay S Jaiswal, Vasantharajan Janakiraman, Noelyn M Kljavin and 6 more
PLoS ONE · 2009
doi:10.1371/journal.pone.0005717
Cited by papers we hold 1
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.